Transitioning to long-acting insulin for a 1-2 hour overlap at the time of DKA resolution has decreased the glycemic variability between intravenous and subcutaneous injections of insulin and reduced episodes of rebound hyperglycemia [5]. This evidence concerns the gene INS and Hyperglycemia.